- Vienna '18
- Athens 2019
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: P.Ramos PORTUGAL
Co Author(s): J. Rosendo K. Sousa A. Pepo A. Candeias
Back to previous
To describe the safety and efficacy of intravitreal bevacizumab injection in 2 patients with refractory cystoid macular edema (CME) after an uncomplicated cataract surgery (Irvine-Gass Syndrome)
The authors describe a two case report of the ophthalmology department of the Hospital Espirito Santo de Évora, Portugal.
Two patients with pseudophakic CME after an uncomplicated cataract surgery refractory to medical treatment (topical NSAIDs and topical corticosteroid). They underwent intravitreal bevacizumab injections. The main outcome measures were best-corrected visual acuity (BCVA) and retinal thickness on optical coherence tomography (OCT).
OCT confirmed the diagnosis of pseudophakic CME in both cases. The median duration of CME before treatment with intravitreal bevacizumab was 18 weeks (16-19 weeks). The initial BCVA was 20/100 in the first case and 20/50 in the second case. After 2 injections of intravitreal bevacizumab, they demonstrated improvement of BCVA (> 2 Early Treatment Diabetic Retinopathy Study [ETDRS] lines). The central macular thickness (CMT) measured with OCT was 619??m at baseline in the first case, 555??m in the second case and decreased to a mean of 295??m at the final follow-up. No ocular or systemic adverse events were observed.
Intravitreal bevacizumab injections were safe and appeared to be an effective treatment of macular edema related to Irvine-Gass syndrome. Treated eyes had a significant improvement in best corrected visual acuity and decrease in macular thickness by optical coherence tomography.